+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Febuxostat"

From
Gout Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • April 2025
  • 93 Pages
  • Global
From
Gout Therapeutics Market Report 2025 - Product Thumbnail Image

Gout Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
Gout - Pipeline Insight, 2024 - Product Thumbnail Image

Gout - Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 80 Pages
  • Global
From
Gout: Opportunity Assessment and Forecast - Update - Product Thumbnail Image

Gout: Opportunity Assessment and Forecast - Update

  • Report
  • December 2024
  • 65 Pages
  • Global
From
From
Gout - Opportunity Assessment and Forecast - Product Thumbnail Image

Gout - Opportunity Assessment and Forecast

  • Report
  • December 2023
  • 62 Pages
  • Global
From
  • 12 Results (Page 1 of 1)
Loading Indicator

Febuxostat is a medication used to treat hyperuricemia, a condition in which the body produces too much uric acid. It is used to reduce the risk of gout flares and to prevent the formation of kidney stones. Febuxostat is a xanthine oxidase inhibitor, which works by blocking the enzyme that produces uric acid. It is used in combination with lifestyle changes, such as reducing alcohol consumption and avoiding certain foods, to reduce the risk of gout flares. Febuxostat is a part of the immune disorders drugs market, which includes medications used to treat a variety of conditions related to the immune system. These drugs are used to treat autoimmune diseases, such as rheumatoid arthritis, lupus, and psoriasis, as well as allergies and asthma. They can also be used to treat certain types of cancer. Companies in the Febuxostat market include AstraZeneca, Merck, Pfizer, and Takeda Pharmaceuticals. Show Less Read more